Welcome to Neurokos

Neurokos, Inc. is a privately held, clinical stage, biopharmaceutical company, focusing on the research and development of first-in-class therapies that have the potential to change the treatment paradigm in neurology.

Neurodegenerative diseases are our first area of focus.

Our lead candidate is a clinical stage, first-in-class, Disease Modifying therapy for Alzheimer's disease.

"Neurokos" is derived from the greek words "neuro" for nerve and "akos" for cure.

"Over 1.5 billion people worldwide, including over 100 million people in the U.S, suffer from CNS disorders".

"Direct and indirect costs of Alzheimer's disease and other dementias in the US alone are over $150 billion/year".